AXSM Axsome Therapeutics Inc.

+1.78  (+8%)
Previous Close 22.85
Open 23
Price To Book 34.69
Market Cap 847,728,985
Shares 34,418,554
Volume 915,807
Short Ratio
Av. Daily Volume 1,015,663

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data met primary endpoint - April 15, 2019.
Smoking cessation
Phase 2/3 top-line data due 1H 2020.
Agitation in patients with Alzheimer’s disease (AD)
Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.
Complex regional pain syndrome (CRPS)
Phase 3 data due 2H 2019.
Treatment resistant depression
Phase 3 interim efficacy analysis January 9, 2017 recommended trial continue to full enrollment.
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 top-line data due 2H 2019.
Phase 3 trial initiation announced June 24, 2019 with data due 2H 2019.
Major Depressive Disorder
Phase 2 top-line data due 2H 2019.

Latest News

  1. Edited Transcript of AXSM earnings conference call or presentation 8-Aug-19 12:00pm GMT
  2. Axsome Therapeutics, Inc. (AXSM) Q2 2019 Earnings Call Transcript
  3. Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
  4. Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019
  5. Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
  6. About to Buy Penny Stocks? Look at These 3 Companies First
  7. Implied Volatility Surging for Axsome (AXSM) Stock Options
  8. 5 Best Biotech Stocks of 2019 So Far
  9. Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019
  10. The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
  11. Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes
  12. Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)
  13. Axsome Initiates Phase III Study on Depression Candidate
  14. Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
  15. 3 Stocks the World's Best Investors Are Buying Right Now
  16. Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
  17. Do Institutions Own Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares?
  18. 3 Top Small-Cap Stocks to Buy in June
  19. Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting
  20. These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month